See more : SOPHiA GENETICS SA (SOPH) Income Statement Analysis – Financial Results
Complete financial analysis of Bicycle Therapeutics plc (BCYC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bicycle Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Safer Shot, Inc. (SAFS) Income Statement Analysis – Financial Results
- Cellectis S.A. (CLLS) Income Statement Analysis – Financial Results
- Mayfair Gold Corp. (MFG.V) Income Statement Analysis – Financial Results
- Sleepz AG (SLZ.WA) Income Statement Analysis – Financial Results
- Imperial Brands PLC (IMB.L) Income Statement Analysis – Financial Results
Bicycle Therapeutics plc (BCYC)
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.98M | 14.46M | 11.70M | 10.39M | 13.80M | 7.14M | 2.06M | 0.00 |
| Cost of Revenue | 6.47M | 3.69M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 269.29K |
| Gross Profit | 20.51M | 10.78M | -33.18M | -22.76M | -11.74M | -13.63M | -9.81M | -269.29K |
| Gross Profit Ratio | 76.03% | 74.51% | -283.69% | -219.05% | -85.06% | -190.93% | -476.02% | 0.00% |
| Research & Development | 156.50M | 81.61M | 44.88M | 33.15M | 25.54M | 20.76M | 11.87M | 9.77M |
| General & Administrative | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.78M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -325.11K |
| SG&A | 59.83M | 49.51M | 32.44M | 29.20M | 14.56M | 8.12M | 6.41M | 3.45M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -5.38M | -665.00K | -119.00K | 0.00 |
| Operating Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.22M |
| Cost & Expenses | 216.92M | 131.12M | 77.32M | 62.35M | 40.10M | 28.88M | 18.27M | 13.49M |
| Interest Income | 14.00M | 5.76M | 120.00K | 683.00K | 814.00K | 169.00K | 50.00K | 8.00K |
| Interest Expense | 3.26M | 3.34M | 2.98M | 457.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55M | 3.69M | 1.41M | 1.29M | 963.97K | 710.80K | 335.56K | 269.29K |
| EBITDA | -183.40M | -112.96M | -64.08M | -50.39M | -30.03M | -21.49M | -15.88M | -13.26M |
| EBITDA Ratio | -679.86% | -766.76% | -559.96% | -493.52% | -190.56% | -294.76% | -770.92% | 0.00% |
| Operating Income | -189.95M | -116.65M | -65.62M | -51.96M | -26.30M | -21.75M | -16.21M | -13.49M |
| Operating Income Ratio | -704.13% | -806.56% | -560.98% | -500.10% | -190.56% | -304.74% | -787.04% | 0.00% |
| Total Other Income/Expenses | 10.74M | 2.41M | -2.86M | 226.00K | -4.56M | -496.00K | -69.00K | -37.90K |
| Income Before Tax | -179.21M | -114.24M | -68.48M | -51.73M | -30.86M | -22.24M | -16.28M | -13.53M |
| Income Before Tax Ratio | -664.32% | -789.88% | -585.47% | -497.92% | -223.62% | -311.69% | -790.39% | 0.00% |
| Income Tax Expense | 1.46M | -1.52M | -1.66M | -724.00K | -254.00K | -396.00K | -23.00K | -20.94K |
| Net Income | -180.66M | -112.72M | -66.82M | -51.01M | -30.61M | -21.85M | -16.26M | -13.51M |
| Net Income Ratio | -669.72% | -779.35% | -571.25% | -490.95% | -221.78% | -306.14% | -789.27% | 0.00% |
| EPS | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| EPS Diluted | -5.08 | -3.80 | -2.67 | -2.66 | -2.77 | -1.64 | -1.22 | -0.76 |
| Weighted Avg Shares Out | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
| Weighted Avg Shares Out (Dil) | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 13.29M | 13.29M | 17.70M |
Bicycle Therapeutics Is Looking Increasingly Attractive
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Source: https://incomestatements.info
Category: Stock Reports